Damora Therapeutics, Inc. Stock: price and insider trades · United States

Damora Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 13 filings signed by 9 insiders.

On the market, 1 insider bought (1 purchase totalling €222k) while 1 insider sold (1 sale totalling €6,422). Netting one side against the other leaves €216k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €222k, bought by Jarrett Jennifer and made public on 28 September 2026 (0.020% of market cap). On the buying side, the filings list 1 chief executive among the declarants.

The last purchase on record was published on 28 September 2026, which is 20 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade.

With 13 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Our records for Damora Therapeutics, Inc. go back to 2021, with 12 purchases and 8 sales on the open market in total.

In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.